Clinical study of a new anti-inflammatory drug: 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370).
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001168:Arthritis / Q000188:drug therapy*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001663:Bilirubin / Q000097:blood; D001772:Blood Cell Count; D002986:Clinical Trials as Topic; D004231:Diuresis / Q000187:drug effects; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy; D010919:Placebos; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D013729:Terpenes / Q000009:adverse effects / Q000627:therapeutic use*; D000637:Transaminases / Q000097:blood; D014527:Uric Acid / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D010919:Placebos; D011720:Pyrazoles; D013729:Terpenes; D014527:Uric Acid; D000637:Transaminases; D001663:Bilirubin; D007213:Indomethacin